Abstract

Quality Control: Driving Standardization For Commercially-Available iPSC-derived Cell Types

Greg Luerman, Technical Director, Axiogenesis AG

Stem cell technologies have revolutionized our industry. In addition to humanizing drug discovery, these differentiated tissues now closely mirror the existing biology and physiology of an adult tissue system. This provides an ideal system for drug toxicity testing, disease modeling, and efficacy screening. For these cells to see further adoption into the industry, tight quality control metrics must be in place to guarantee reproducible results. Axiogenesis is helping to drive the establishment of industry-wide QC standards for iPS cell products.